May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 20, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Jan 14, 2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Nov 13, 2019
Otsuka Announces Retirement of President & Chief Executive Officer William H. Carson, M.D.
Oct 30, 2019
Global Schizophrenia Drugs (Orals & Injectables) Market Insights, Trends and Forecasts, 2013-2018 & 2019-2023
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Oct 04, 2019
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Sep 11, 2019
Similar Response Rate but Higher Degrees of Clinical Improvement Were More Likely to Achieve With Cariprazine Compared to Risperidone - A Study by Gedeon Richter Plc
Jul 23, 2019
Schizophrenia Drugs Market Growth, Trends, and Forecast 2019-2024
Jul 15, 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
May 30, 2019
Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA
May 28, 2019
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
May 15, 2019
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment to Mental Health
Apr 16, 2019
Cariprazine Shows Better Cognitive Improving Features and Uniquely Favorable Weight Gain Effect Compared to Other Antipsychotics
Apr 09, 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
Apr 01, 2019
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society